Marshall Financial Group LLC Cuts Position in Medpace Holdings, Inc. $MEDP

Marshall Financial Group LLC lessened its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 35.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,006 shares of the company’s stock after selling 1,108 shares during the quarter. Marshall Financial Group LLC’s holdings in Medpace were worth $1,127,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the company. AQR Capital Management LLC boosted its holdings in shares of Medpace by 65.1% in the 3rd quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock worth $518,170,000 after purchasing an additional 404,226 shares in the last quarter. Norges Bank bought a new stake in Medpace in the 2nd quarter worth approximately $66,597,000. Arrowstreet Capital Limited Partnership lifted its position in Medpace by 205.8% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock worth $161,523,000 after buying an additional 211,411 shares during the last quarter. Clarkston Capital Partners LLC purchased a new stake in Medpace in the second quarter worth approximately $40,569,000. Finally, Bares Capital Management Inc. boosted its stake in Medpace by 319.2% in the second quarter. Bares Capital Management Inc. now owns 157,084 shares of the company’s stock worth $49,302,000 after buying an additional 119,608 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Insider Activity at Medpace

In other news, President Jesse J. Geiger sold 31,707 shares of the stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the completion of the sale, the president directly owned 15,000 shares in the company, valued at approximately $6,829,500. This represents a 67.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 20.30% of the company’s stock.

Medpace Stock Performance

NASDAQ:MEDP opened at $452.51 on Monday. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $628.92. The firm has a market cap of $12.84 billion, a PE ratio of 29.58, a price-to-earnings-growth ratio of 2.17 and a beta of 1.44. The business has a 50 day moving average price of $509.09 and a 200-day moving average price of $538.69.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Monday, February 9th. The company reported $4.67 EPS for the quarter, beating analysts’ consensus estimates of $4.18 by $0.49. The company had revenue of $708.45 million during the quarter, compared to analyst estimates of $689.53 million. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The firm’s revenue was up 32.0% compared to the same quarter last year. During the same period in the prior year, the business posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Research analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Royal Bank Of Canada initiated coverage on shares of Medpace in a research note on Tuesday, March 3rd. They set an “outperform” rating and a $522.00 price target on the stock. BMO Capital Markets reaffirmed a “market perform” rating on shares of Medpace in a research note on Wednesday, February 11th. Mizuho set a $582.00 target price on shares of Medpace in a report on Wednesday, February 11th. Weiss Ratings reiterated a “buy (b)” rating on shares of Medpace in a research report on Wednesday, January 28th. Finally, Zacks Research downgraded shares of Medpace from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 12th. Five investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Medpace currently has a consensus rating of “Hold” and an average target price of $486.67.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.